Amylyx Pharmaceuticals, Inc. (AMLX) Operating income 2021–2025
Amylyx Pharmaceuticals, Inc. (AMLX) annual operating income history from SEC filings — each fiscal year as reported.
-$153.3MFY2025 · since FY2021: -$82.7M → -$153.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$153.3M | +51.3% |
| FY2024 | -$314.7M | -911.1% |
| FY2023 | $38.8M | +119.3% |
| FY2022 | -$201.3M | -143.5% |
| FY2021 | -$82.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More AMLX financial trends
AMLX RevenueAMLX Net incomeAMLX Net marginAMLX Gross profitAMLX Gross marginAMLX Operating marginAMLX Operating cash flowAMLX Free cash flowAMLX Capital expendituresAMLX Return on equityAMLX Stock buybacksAMLX Dividends paidAMLX Total assetsAMLX Total liabilitiesAMLX Shareholders’ equityAMLX overview →